Publisher： Karger
E-ISSN： 1423-0232|65|2|46-49
ISSN： 0030-2414
Source： Oncology, Vol.65, Iss.2, 2003-11, pp. : 46-49
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Recent literature about the treatment options of small cell lung cancer stresses the role of ifosfamide both alone and in combination with either cisplatin or carboplatin and etoposide. Its pharmacokinetics and the lower hematological toxicity permit the use of high doses which seem to be more effective in this very sensitive tumor. However, despite the increment in the response rate, in both limited and extended disease, the overall and long-term survival seems to be little influenced by therapy. Newer strategies combining old and new therapeutic approaches have to be explored to overcome the lack of progresses registered in these years.
Related content
Ifosfamide in Non-Small Cell Lung Cancer
Oncology, Vol. 65, Iss. 2, 2003-11 ,pp. :
Access to resources
Recommend
Vinorelbine and Alternating Cisplatin and Ifosfamide in the Treatment of Non-Small Cell Lung Cancer
Oncology, Vol. 58, Iss. 1, 2000-01 ,pp. :
Oncology, Vol. 56, Iss. 4, 1999-05 ,pp. :
Oncology, Vol. 69, Iss. 4, 2005-12 ,pp. :